Patents by Inventor Sumana Chandramouli

Sumana Chandramouli has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250009874
    Abstract: Described are mutant, human cytomegalovirus (HCMV) pentamer complex polypeptides, methods of making them, and their use in HCMV protein complexes and compositions. In particular, the use of the modified HCMV polypeptides to stabilize HCMV complexes or unmask a pentamer epitope is described.
    Type: Application
    Filed: April 30, 2024
    Publication date: January 9, 2025
    Applicant: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Enrico MALITO, Sumana CHANDRAMOULI, Andrea CARFI, Matthew BOTTOMLEY
  • Publication number: 20240383949
    Abstract: Described are mutant human cytomegalovirus (HCMV) pentamer complex polypeptides, methods of making them, and their use in HCMV protein complexes and compositions. In particular, the use of the modified HCMV polypeptides to stabilize HCMV complexes or unmask a pentamer epitope is described.
    Type: Application
    Filed: February 7, 2024
    Publication date: November 21, 2024
    Applicant: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Enrico MALITO, Matthew James BOTTOMLEY, Andrea CARFI, Sumana CHANDRAMOULI, Kate LUISI
  • Publication number: 20240207392
    Abstract: The disclosure relates to Epstein-Barr virus ribonucleic acid vaccines as well as methods of using the vaccines and compositions comprising the vaccines.
    Type: Application
    Filed: April 13, 2022
    Publication date: June 27, 2024
    Applicant: ModernaTX, Inc.
    Inventors: Sumana Chandramouli, Brooke Bollman, Yen-Ting Lai, Guillaume Stewart-Jones, Andrea Carfi
  • Patent number: 11932669
    Abstract: Described are mutant human cytomegalovirus (HCMV) pentamer complex polypeptides, methods of making them, and their use in HCMV protein complexes and compositions. In particular, the use of the modified HCMV polypeptides to stabilize HCMV complexes or unmask a pentamer epitope is described.
    Type: Grant
    Filed: April 6, 2021
    Date of Patent: March 19, 2024
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Enrico Malito, Matthew James Bottomley, Andrea Carfi, Sumana Chandramouli, Kate Luisi
  • Publication number: 20230248820
    Abstract: Described are mutant, human cytomegalovirus (HCMV) pentamer complex polypeptides, methods of making them, and their use in HCMV protein complexes and compositions. In particular, the use of the modified HCMV polypeptides to stabilize HCMV complexes or unmask a pentamer epitope is described.
    Type: Application
    Filed: April 18, 2018
    Publication date: August 10, 2023
    Inventors: Enrico Malito, Sumana Chandramouli, Andrea Carfi, Matthew Bottomley
  • Publication number: 20230201334
    Abstract: Modified HCMV gB proteins in a non-post-fusogenic conformation, compositions comprising such proteins, and uses thereof.
    Type: Application
    Filed: July 22, 2020
    Publication date: June 29, 2023
    Applicant: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Marco BIANCUCCI, Sumana CHANDRAMOULI, Newton Muchugu WAHOME
  • Publication number: 20230174626
    Abstract: Monoclonal antibodies and antigen binding fragments that specifically bind to the Human Cytomegalovirus (HCMV) pentamer protein complex (gH/gL/UL128/UL130/UL131A) or other gH-containing complexes, and uses thereof.
    Type: Application
    Filed: March 25, 2021
    Publication date: June 8, 2023
    Applicant: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Marco BIANCUCCI, Sumana CHANDRAMOULI, Kate LUISI
  • Publication number: 20210292395
    Abstract: Methods, compositions, processes, and uses related to recombinant RSV soluble F protein polypeptides are provided.
    Type: Application
    Filed: July 30, 2019
    Publication date: September 23, 2021
    Applicant: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Kunal BAKSHI, Marcin Krzysztof BUGNO, Sumana CHANDRAMOULI, Matthew Albert TYSON, Zihao WANG, Mark Jonathan WILSON
  • Publication number: 20210277067
    Abstract: Described are mutant human cytomegalovirus (HCMV) pentamer complex polypeptides, methods of making them, and their use in HCMV protein complexes and compositions. In particular, the use of the modified HCMV polypeptides to stabilize HCMV complexes or unmask a pentamer epitope is described.
    Type: Application
    Filed: April 6, 2021
    Publication date: September 9, 2021
    Inventors: Enrico MALITO, Matthew James BOTTOMLEY, Andrea CARFI, Sumana CHANDRAMOULI, Kate LUISI
  • Patent number: 10364273
    Abstract: The invention generally relates to recombinant human cytomegalovirus (CMV) gB proteins and immunogenic fragments thereof, which do not comprise a transmembrane (TM) domain; and comprise one or more mutations that reduce the aggregation between the monomeric trimers of gB, and/or adhesion of the monomeric trimer of gB to the host cell.
    Type: Grant
    Filed: December 7, 2015
    Date of Patent: July 30, 2019
    Assignee: GLAXOSMITHKLINE BIOLOGICALS S.A.
    Inventors: Andrea Carfi, Sumana Chandramouli, Ethan C. Settembre
  • Publication number: 20180265551
    Abstract: The invention generally relates to recombinant human cytomegalovirus (CMV) gB proteins and immunogenic fragments thereof, which do not comprise a transmembrane (TM) domain; and comprise one or more mutations that reduce the aggregation between the monomeric trimers of gB, and/or adhesion of the monomeric trimer of gB to the host cell.
    Type: Application
    Filed: December 7, 2015
    Publication date: September 20, 2018
    Applicant: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Andrea CARFI, Sumana CHANDRAMOULI, Ethan C. SETTEMBRE
  • Patent number: 10030052
    Abstract: The present invention is directed to mutant parvovirus VP1 unique region polypeptides, compositions comprising such polypeptides, methods of making such compositions, as well as methods for identifying the likely presence of parvovirus-neutralizing antibodies, and methods for assessing the functional immunogenicity of parvovirus vaccines and measuring a correlate of efficacy to assess a treatment for parvovirus infection.
    Type: Grant
    Filed: July 25, 2012
    Date of Patent: July 24, 2018
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Ethan Settembre, Sumana Chandramouli
  • Publication number: 20140170187
    Abstract: The present invention is directed to mutant parvovirus VP1 unique region polypeptides, compositions comprising such polypeptides, methods of making such compositions, as well as methods for identifying the likely presence of parvovirus-neutralizing antibodies, and methods for assessing the functional immunogenicity of parvovirus vaccines and measuring a correlate of efficacy to assess a treatment for parvovirus infection.
    Type: Application
    Filed: July 25, 2012
    Publication date: June 19, 2014
    Inventors: Ethan Settembre, Sumana Chandramouli